ClinicalTrials.gg

Program

GR1803

A development code. Also written as “GR1803 injection” and “Velinotamig specified dose on specified days.”.

Its studies are mostly in Multiple Myeloma · Purpura, Thrombocytopenic, Idiopathic · Lupus Erythematosus, Systemic, led by 2 companies.

Furthest: phase 3, since Feb 28, 20267 company-led studies, 6 open or runningNext primary completion: May 12, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chongqing Genrix Biopharmaceutical65 open or runningphase 3since Feb 28, 2026Aug 20, 2024May 12, 2027phase 2 · NCT06566547
Cullinan Therapeutics11 open or runningphase 2since Jul 28, 2026Jul 28, 2026Jan 2029phase 2 · NCT07738822

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 20, 2024First study: phase 2 study in Multiple MyelomaNew to Chongqing Genrix BiopharmaceuticalChongqing Genrix Biopharmaceutical · NCT06566547 · 116 enrolled · China
  2. Apr 23, 2025Phase 2 study in Multiple MyleomaChongqing Genrix Biopharmaceutical · NCT06952075 · 30 planned · China
  3. Jul 21, 20252 phase 2 studies in Multiple MyelomaChongqing Genrix Biopharmaceutical · NCT07090954, NCT07102706
  4. Dec 25, 2025Phase 2 study in Lupus Erythematosus, SystemicChongqing Genrix Biopharmaceutical · NCT07348055 · 44 planned · China
  5. Feb 28, 2026Phase 3 study in Multiple MyelomaPhase 3 reachedChongqing Genrix Biopharmaceutical · NCT07452198 · 358 planned · China
  6. Jul 28, 2026Cullinan Therapeutics's first study: phase 2 study in Purpura, Thrombocytopenic, IdiopathicNew to Cullinan TherapeuticsCullinan Therapeutics · NCT07738822 · 72 planned · United States

Ahead

  1. May 12, 2027Primary completion: phase 2 study in Multiple MyelomaChongqing Genrix Biopharmaceutical · NCT06566547
  2. Jun 1, 2027Primary completion: phase 2 study in Lupus Erythematosus, SystemicChongqing Genrix Biopharmaceutical · NCT07348055
  3. Jul 1, 2027Primary completion: phase 2 study in Multiple MyleomaChongqing Genrix Biopharmaceutical · NCT06952075
  4. Jan 2029Primary completion: phase 2 study in Purpura, Thrombocytopenic, IdiopathicCullinan Therapeutics · NCT07738822

TargetBeta

CD3E →read by rule
“A Phase I Monotherapy Study Assessing the Safety and Efficacy of GR1803, a BCMA×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma”study text, by rule · the study

Other programs on CD3E

ProgramCompanyFurthest phaseStudies
etentamigAbbViephase 311
obrixtamigBoehringer Ingelheimphase 311
surovatamigAstraZenecaphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
cevostamabHoffmann-La Rochephase 38
ramantamigJohnson & Johnsonphase 37
pasritamigJohnson & Johnsonphase 35
TQB2825Sino Biopharmaceuticalphase 35
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 34
gocatamigMerckphase 34
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492AstraZenecaphase 22

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07738822Purpura, Thrombocytopenic, Idiopathic · United States2Not yet recruitingCullinan TherapeuticsJan 202972
NCT07452198Multiple Myeloma · China3RecruitingChongqing Genrix BiopharmaceuticalMar 2029358
NCT07348055Lupus Erythematosus, Systemic · China2RecruitingChongqing Genrix BiopharmaceuticalJun 1, 202744
NCT07102706Multiple Myeloma · China2CompletedChongqing Genrix BiopharmaceuticalMay 20, 202576
NCT07090954Multiple Myeloma · China2Not yet recruitingChongqing Genrix BiopharmaceuticalJul 31, 202632
NCT06952075Multiple Myleoma · China2RecruitingChongqing Genrix BiopharmaceuticalJul 1, 202730
NCT06566547Multiple Myeloma · China2Active, not recruitingChongqing Genrix BiopharmaceuticalMay 12, 2027116

How it is read

Names in the registry

  • “GR1803 injection”, 5 entries
  • “Velinotamig specified dose on specified days.”, 1 entry
  • “GR1803”, 1 entry

Codes read as this program: GR1803.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.